| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/31/2001 | DE10058310A1 2-(3,5-Bistrifluormethylphenyl)-N-methyl-N-(6- morpholin-4-yl-4-o-tolylpyridin -3-yl ) isobutyramid 2- (3,5-Bis-trifluoromethyl) -N-methyl-N- (6-morpholin-4-yl-4-o-tolylpyridine -3-yl) -isobutyramide |
| 05/31/2001 | CA2706113A1 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| 05/31/2001 | CA2704975A1 Therapeutic intervention to mimic the effect of caloric restriction |
| 05/31/2001 | CA2395564A1 Novel compounds |
| 05/31/2001 | CA2395049A1 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 05/31/2001 | CA2393126A1 Isolation of five novel genes coding for new fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma |
| 05/31/2001 | CA2392697A1 Phosphorus-containing dendrimers as transfection agents |
| 05/31/2001 | CA2392576A1 .beta.-amino acid-, aspartic acid- and diaminopropionic-based inhibitors of factor xa |
| 05/31/2001 | CA2392375A1 Synthetic oligomannosides, preparation and uses thereof |
| 05/31/2001 | CA2392369A1 Treatment of heart rhythm disturbances with n6-substituted-5'-(n-substituted) carboxamidoadenosines |
| 05/31/2001 | CA2392365A1 Method for increasing the concentration of ascorbic acid in brain tissues of a subject |
| 05/31/2001 | CA2392362A1 Novel methods and compositions involving opioids and antagonists thereof |
| 05/31/2001 | CA2392356A1 Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs |
| 05/31/2001 | CA2392353A1 Stable acid labile benzimidazole pharmaceutical compositions |
| 05/31/2001 | CA2392327A1 Imidazo-pyridine derivatives as ligands for gaba receptors |
| 05/31/2001 | CA2392272A1 Modified adenovirus fibre and uses |
| 05/31/2001 | CA2392225A1 Novel il-8 receptor antagonists |
| 05/31/2001 | CA2392149A1 2-arylquinoline derivatives, preparation and therapeutic use thereof |
| 05/31/2001 | CA2391962A1 Multilayer preparation for a controlled, pulsed release of active substances |
| 05/31/2001 | CA2391575A1 Heterocyclic ketone and thioester compounds and uses |
| 05/31/2001 | CA2391526A1 A pharmaceutical composition for treatment of diseases associated with decrease in bone mass |
| 05/31/2001 | CA2391457A1 Phytosterol and phytostanol compositions |
| 05/31/2001 | CA2391288A1 Ethers of o-desmethyl venlafaxine |
| 05/31/2001 | CA2391145A1 Method of preparing clarithromycin |
| 05/31/2001 | CA2391103A1 Pyrazolo¬1,5-d|¬1,2,4|triazines for enhancing cognition |
| 05/31/2001 | CA2391012A1 Pyrazinone thrombin inhibitors |
| 05/31/2001 | CA2390923A1 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| 05/31/2001 | CA2390724A1 Combination of fluazuron and invermectin for parasite control |
| 05/31/2001 | CA2390465A1 Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies |
| 05/31/2001 | CA2389869A1 Preparation for nasal administration |
| 05/31/2001 | CA2389679A1 Novel sulfonyloxazolamines |
| 05/31/2001 | CA2389568A1 Osmotic dosage form comprising first and second coats |
| 05/31/2001 | CA2389547A1 Injectable preparation for controlling fish live comprising benzoyl urea derivatives |
| 05/31/2001 | CA2388103A1 Medicament and combination of compatible medicaments |
| 05/31/2001 | CA2387591A1 Use of indirubine derivatives for making medicines |
| 05/31/2001 | CA2387575A1 Coating |
| 05/31/2001 | CA2386955A1 Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
| 05/30/2001 | EP1103562A1 Novel g-protein coupled receptor protein and dna thereof |
| 05/30/2001 | EP1103559A1 Autoimmune nucleosides |
| 05/30/2001 | EP1103554A1 Derivatives of dihydrofuro-(3,4-b)-quinolein-1-ones, process of préparation and phamaceutical compositions containing them |
| 05/30/2001 | EP1103553A2 Substituted heterocyclic derivatives |
| 05/30/2001 | EP1103546A1 Process for preparation of pyridine derivatives |
| 05/30/2001 | EP1103545A1 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide |
| 05/30/2001 | EP1103544A2 Piperidine derivatives and antiplatelet agents containing the same |
| 05/30/2001 | EP1103266A2 Formulations of curcumine |
| 05/30/2001 | EP1103263A2 Poly-L-lactates as antitumour agents |
| 05/30/2001 | EP1103262A1 Antifungal solutions |
| 05/30/2001 | EP1103261A1 Remedies or preventives for intractable epilepsy |
| 05/30/2001 | EP1103260A2 Transdermal system for the administration of clonidine |
| 05/30/2001 | EP1103259A1 Use of y-butyrobetaine salts for the preparation of compositions suitable for human or animal nutrition |
| 05/30/2001 | EP1103258A1 Solid preparation containing sparingly soluble nsaids |
| 05/30/2001 | EP1103257A2 Method for treating migraine symptoms using acetominophen |
| 05/30/2001 | EP1103256A1 Use of ketamine for the treatment of neuroendocrine immune dysfunction und algogenic psychosyndrome |
| 05/30/2001 | EP1103255A1 Method of rearing and feeds |
| 05/30/2001 | EP1103252A1 Pharmaceutical oral preparation of a compound having an antifungic activity, and preparation method |
| 05/30/2001 | EP1103251A1 Use of 1,1-dioxoperhydro-1,2,4-thiadiazines |
| 05/30/2001 | EP1103250A1 Oil-in-polyhydric alcohol type warming base agent comprising sucrose fatty acid ester |
| 05/30/2001 | EP1103243A2 Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance p |
| 05/30/2001 | EP1103190A1 Feed for prevention and/or treatment of coccidiosis |
| 05/30/2001 | EP1103181A1 Combination of N-phenyl-N'-benzoyl urea derivatives and avermectine compounds for parasite control |
| 05/30/2001 | EP1102862A1 Antisense oligonucleotides targeted to il-15 |
| 05/30/2001 | EP1102859A1 METHOD FOR OBTAINING FATTY ACIDS FROM BIOMASS BY COMBINED $i(IN-SITU) EXTRACTION, REACTION AND CHROMATOGRAPHY USING COMPRESSED GASES |
| 05/30/2001 | EP1102853A1 N-acetylglycosaminyltransferase genes |
| 05/30/2001 | EP1102842A2 Antisense oligonucleotides for the inhibition of vegf expression |
| 05/30/2001 | EP1102838A2 A method of modulating the efficiency of translation termination and degradation of aberrant mrna involving a surveillance complex comprising human upf1p, eucaryotic release factor 1 and eucaryotic release factor 3 |
| 05/30/2001 | EP1102790A2 Immunological herpes simplex virus antigens and methods for use thereof |
| 05/30/2001 | EP1102787A1 2'-o-aminoethyloxyethyl-modified oligonucleotides |
| 05/30/2001 | EP1102784A1 A compound containing a labile disulfide bond |
| 05/30/2001 | EP1102783A1 Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom |
| 05/30/2001 | EP1102781A1 New cofactors for methyltransferases |
| 05/30/2001 | EP1102776A1 Water soluble prodrugs of hindered alcohols or phenols |
| 05/30/2001 | EP1102775A1 Novel phospholipids with unsaturated alkyl and acyl chains |
| 05/30/2001 | EP1102769A2 Tricyclic carboxamides |
| 05/30/2001 | EP1102768A1 Substituted pyrazole derivatives condensed with six-membered heterocyclic rings |
| 05/30/2001 | EP1102767A1 Substituted pyrazole derivatives |
| 05/30/2001 | EP1102766A1 Triazolopyridines for the treatment of thrombosis disorders |
| 05/30/2001 | EP1102763A2 Fsh mimetics for the treatment of infertility |
| 05/30/2001 | EP1102762A2 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists |
| 05/30/2001 | EP1102761A2 Cyclopentabenzofuran derivatives and their use |
| 05/30/2001 | EP1102758A1 Particle-forming compositions containing fused pyrrolocarbazoles |
| 05/30/2001 | EP1102757A1 Substituted oxazole and thiazole derivatives as hppar gamma and hppar alpha activators |
| 05/30/2001 | EP1102756A1 Aza-heterocyclic compounds used to treat neurological disorders and hair loss |
| 05/30/2001 | EP1102755A1 Substituted isoxazole derivatives as estrogen receptor modulators |
| 05/30/2001 | EP1102754A1 Imidazoles and related compounds as alpha-1a agonists |
| 05/30/2001 | EP1102753A2 Pyrazoles as estrogen receptor modulators |
| 05/30/2001 | EP1102752A1 Succinoylamino lactams as inhibitors of a beta protein production |
| 05/30/2001 | EP1102751A1 Novel bi- and tri-cyclic aza compounds and their uses |
| 05/30/2001 | EP1102750A1 Amide derivatives useful as inhibitors of the production of cytokines |
| 05/30/2001 | EP1102748A1 New 4-amino-1-aryl-pyridine-2-ones with anticonvulsive action and method for producing same |
| 05/30/2001 | EP1102747A1 Crystalline forms of osanetant |
| 05/30/2001 | EP1102746A1 Substituted phenylamidines with antithrombotic action |
| 05/30/2001 | EP1102745A1 A process for the preparation of zofenopril calcium salt |
| 05/30/2001 | EP1102743A1 Amide derivatives which are useful as cytokine inhibitors |
| 05/30/2001 | EP1102742A2 Compounds and compositions for delivering active agents |
| 05/30/2001 | EP1102739A1 Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders |
| 05/30/2001 | EP1102598A1 Hair growth/maintenance compositions and methods involving the same |
| 05/30/2001 | EP1102597A1 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5ht 4 receptors |
| 05/30/2001 | EP1102594A1 Use of camptothecin derivatives, with reduced gastrointestinal toxicity |
| 05/30/2001 | EP1102593A1 Prostate formula |
| 05/30/2001 | EP1102592A1 Coumarin and related aromatic-based polymeric prodrugs |